290 related articles for article (PubMed ID: 16983701)
1. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma.
Suppiah R; Shaheen PE; Elson P; Misbah SA; Wood L; Motzer RJ; Negrier S; Andresen SW; Bukowski RM
Cancer; 2006 Oct; 107(8):1793-800. PubMed ID: 16983701
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of platelet count in patients with renal cell carcinoma.
Erdemir F; Kilciler M; Bedir S; Ozgok Y; Coban H; Erten K
Urol Int; 2007; 79(2):111-6. PubMed ID: 17851278
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of thrombocytosis in renal cell carcinoma.
Bensalah K; Leray E; Fergelot P; Rioux-Leclercq N; Tostain J; Guillé F; Patard JJ
J Urol; 2006 Mar; 175(3 Pt 1):859-63. PubMed ID: 16469566
[TBL] [Abstract][Full Text] [Related]
4. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma.
Ito K; Asano T; Yoshii H; Satoh A; Sumitomo M; Hayakawa M
Int J Urol; 2006 Nov; 13(11):1365-70. PubMed ID: 17083384
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of thrombocytosis in renal cell carcinoma patients.
Inoue K; Kohashikawa K; Suzuki S; Shimada M; Yoshida H
Int J Urol; 2004 Jun; 11(6):364-7. PubMed ID: 15157203
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of renal vein and inferior vena cava involvement in renal cell carcinoma.
Wagner B; Patard JJ; Méjean A; Bensalah K; Verhoest G; Zigeuner R; Ficarra V; Tostain J; Mulders P; Chautard D; Descotes JL; de la Taille A; Salomon L; Prayer-Galetti T; Cindolo L; Valéri A; Meyer N; Jacqmin D; Lang H
Eur Urol; 2009 Feb; 55(2):452-9. PubMed ID: 18692951
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Mani S; Todd MB; Katz K; Poo WJ
J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941.
Escudier B; Choueiri TK; Oudard S; Szczylik C; Négrier S; Ravaud A; Chevreau C; Venner P; Champagne P; Croteau D; Dupont E; Hariton C; Bukowski RM
J Urol; 2007 Nov; 178(5):1901-5. PubMed ID: 17868728
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
Yoo C; Song C; Hong JH; Kim CS; Ahn H
J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101
[TBL] [Abstract][Full Text] [Related]
10. Impact of macroscopic tumour necrosis to predict survival of patients with surgically resected renal cell carcinoma.
Pflanz S; Brookman-Amissah S; Roigas J; Kendel F; Hoschke B; May M
Scand J Urol Nephrol; 2008; 42(6):507-13. PubMed ID: 19031267
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.
Motzer RJ; Bacik J; Schwartz LH; Reuter V; Russo P; Marion S; Mazumdar M
J Clin Oncol; 2004 Feb; 22(3):454-63. PubMed ID: 14752067
[TBL] [Abstract][Full Text] [Related]
13. Survival analysis of 130 patients with papillary renal cell carcinoma: prognostic utility of type 1 and type 2 subclassification.
Pignot G; Elie C; Conquy S; Vieillefond A; Flam T; Zerbib M; Debré B; Amsellem-Ouazana D
Urology; 2007 Feb; 69(2):230-5. PubMed ID: 17275070
[TBL] [Abstract][Full Text] [Related]
14. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy.
Casamassima A; Picciariello M; Quaranta M; Berardino R; Ranieri C; Paradiso A; Lorusso V; Guida M
J Urol; 2005 Jan; 173(1):52-5. PubMed ID: 15592024
[TBL] [Abstract][Full Text] [Related]
15. Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation.
Nakayama K; Tannir NM; Liu P; Wathen JK; Cheng YC; Champlin RE; Ueno NT
Biol Blood Marrow Transplant; 2007 Aug; 13(8):975-85. PubMed ID: 17640602
[TBL] [Abstract][Full Text] [Related]
16. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases.
Bertini R; Roscigno M; Freschi M; Strada E; Petralia G; Pasta A; Matloob R; Sozzi F; Da Pozzo L; Colombo R; Guazzoni G; Doglioni C; Montorsi F; Rigatti P
J Urol; 2009 May; 181(5):2027-32. PubMed ID: 19286201
[TBL] [Abstract][Full Text] [Related]
17. The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer.
Rodriguez GC; Clarke-Pearson DL; Soper JT; Berchuck A; Synan I; Dodge RK
Obstet Gynecol; 1994 Mar; 83(3):445-8. PubMed ID: 8127540
[TBL] [Abstract][Full Text] [Related]
18. Preoperative thrombocytosis predicts poor survival in patients with glioblastoma.
Brockmann MA; Giese A; Mueller K; Kaba FJ; Lohr F; Weiss C; Gottschalk S; Nolte I; Leppert J; Tuettenberg J; Groden C
Neuro Oncol; 2007 Jul; 9(3):335-42. PubMed ID: 17504931
[TBL] [Abstract][Full Text] [Related]
19. Relation of microvessel density with microvascular invasion, metastasis and prognosis in renal cell carcinoma.
Yildiz E; Ayan S; Goze F; Gokce G; Gultekin EY
BJU Int; 2008 Mar; 101(6):758-64. PubMed ID: 18070177
[TBL] [Abstract][Full Text] [Related]
20. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma.
Shimada H; Oohira G; Okazumi S; Matsubara H; Nabeya Y; Hayashi H; Takeda A; Gunji Y; Ochiai T
J Am Coll Surg; 2004 May; 198(5):737-41. PubMed ID: 15110807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
